Visibuilt, a Danish biotechnology company developing mycelium-based construction materials, has closed a €3.34 million Seed funding round to accelerate the development and market validation of its innovative paving solutions. The round was led by EIFO and Unconventional Ventures, with participation from Proptechfonden and EMDFonden.
The Copenhagen-based company, founded in 2022, is focusing on creating sustainable alternatives to conventional construction binders through its proprietary mycelium technology. The company’s flagship product, visiBINDER, represents a significant departure from traditional carbon-intensive paving materials that have dominated the construction sector for decades.
Scaling Production and Market Validation
The capital injection will be deployed across three primary areas to advance Visibuilt’s commercialization timeline. The funding will enable the company to expand its testing and validation operations, establish production infrastructure capable of supporting large-scale trials, and strengthen both its technical and commercial teams. These steps are essential as the startup transitions from laboratory development toward real-world application and industry adoption.
According to Line Kloster Pedersen, CEO and founder of Visibuilt, “Closing this Seed round is an important milestone for Visibuilt. It enables us to mature our technical platform, validate our solution at a larger scale, and take the next steps towards the market.” This statement underscores the company’s strategic focus on demonstrating the viability of its mycelium-based approach through rigorous field testing before pursuing wider commercial deployment.
Addressing Construction Industry Carbon Footprint
The construction sector, particularly paving and concrete production, remains among Europe’s largest contributors to industrial carbon emissions. Mycelium-based materials offer a compelling alternative by leveraging fungal networks to bind aggregates together, potentially reducing the environmental impact associated with cement-based binders. As regulatory pressure intensifies around embodied carbon in building materials, innovations like Visibuilt’s address a growing market need.
The company’s technology sits within the broader cleantech and advanced materials space, where European startups are increasingly competing to develop scalable alternatives to conventional building components. The involvement of specialized investors such as EIFO and Unconventional Ventures suggests strong confidence in both the technical feasibility and market potential of mycelium-based construction solutions.
European Momentum in Sustainable Construction
This funding announcement reflects the growing momentum in European cleantech innovation, particularly within the construction and materials sectors. As the European Union continues to enforce stricter climate and sustainability regulations, and as major construction companies face pressure to reduce their carbon footprint, demand for low-carbon alternatives is accelerating. Visibuilt’s successful capital raise demonstrates investor appetite for transformative solutions that can address these systemic challenges while maintaining commercial viability.
With total funding now at €3.34 million, Visibuilt enters the next phase of its development with significant resources to validate its approach at scale. The coming months will be critical as the company demonstrates whether mycelium-based materials can meet the rigorous performance standards demanded by the construction industry while delivering the environmental benefits that justify a transition away from entrenched, conventional materials.